Stocks Health care CTXR

NASDAQ · Health care

Citius Pharmaceuticals, Inc. (CTXR)

It posted a net loss of $45.2M. At June 30, 2026 it held $17M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Citius Pharmaceuticals, Inc. does

Citius Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTXR.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Dividends

Citius Pharmaceuticals, Inc. paid $0.60 per share in fiscal 2016.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Citius Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 21, 2026
   Stock exchange listing notice 8-K
2. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026Revenue was $1.5M; diluted EPS -$0.34 versus -$0.80.
3. August 14, 2026
   Quarterly results 8-K
4. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
5. August 5, 2026
   Other event 8-K
6. June 1, 2026
   Other event 8-K
7. May 22, 2026
   Shelf registration to sell securities S-3
8. May 15, 2026
   Quarterly results 8-K
9. May 15, 2026
   Quarterly report 10-Q · period to March 31, 2026Revenue was $1.7M; diluted EPS -$0.95 versus -$1.27.
10. May 8, 2026
    Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 23, 2025. Insider transactions on SEC

Who owns CTXR

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CTXR

What does Citius Pharmaceuticals, Inc. do?

Citius Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTXR.

Is Citius Pharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $45.2M.

When did Citius Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from August 21, 2026.

Similar companies

Compare CTXR with

Compare CTXR with any company

Follow CTXR

Get an email when Citius Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CTXR: get an email when it files

Where the numbers come from

Financial figures are the values Citius Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.